AstraZeneca’s experimental oral therapy saracatinib — originally developed to treat certain cancers — was found to be at least as effective, and even superior to the approved therapies Ofev (nintedanib) and Esbriet (pirfenidone) in treating idiopathic pulmonary fibrosis (IPF) in several preclinical models of the respiratory disease. Saracatinib worked…
From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds to fight pulmonary fibrosis (PF), which is part of a group…
The levels of transforming growth factor-beta-induced protein (TGFBI), a molecule involved in lung development and cancer, are significantly increased in cellular and rodent models of idiopathic pulmonary fibrosis (IPF), a study showed. TGFBI was also found to mediate the pro-scarring effects of transforming growth factor-beta (TGF-beta) — a protein that plays…
The risk of future lung-function decline and mortality in people with idiopathic pulmonary fibrosis (IPF) can be accurately predicted by a deep learning computer algorithm that evaluates CT scans, a study shows. Accurately determining the risk of progression would support early intervention before irreversible damage has occurred, the researchers…
The small molecule TH5487 safely and effectively treated pulmonary fibrosis (PF) in a mouse model, a study reported. Although TH5487 is known to block the activity of the DNA repair enzyme OGG1, its anti-fibrotic effects occurred, in part, by reducing the production of OGG1 itself. According to researchers, these…
The Pulmonary Fibrosis Foundation’s PFF Care Center Network (CCN) now includes 74 medical centers in 34 U.S. states, after six more sites specializing in pulmonary fibrosis (PF) diagnosis, treatment, and patient support joined the nationwide program. “Our new PFF Care Center Network sites offer much-needed comprehensive care for…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EI-1071, an oral anti-inflammatory that Elixiron Immunotherapeutics is developing for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is awarded by the FDA to therapies designed to improve medical care for rare disorders —…
Algernon Pharmaceuticals’ experimental oral therapy NP-120 (ifenprodil) significantly reduced coughing in people with idiopathic pulmonary fibrosis (IPF), according to a new analysis of top-line data from a proof-of-concept Phase 2a clinical trial. The analysis showed the therapy was much more effective at easing cough than previously reported. NP-120’s “potential…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…
The U.S. Food and Drug Administration (FDA) has given fast-track designation to DWN12088, an experimental anti-fibrotic medication that Daewoong Pharmaceutical is developing to treat idiopathic pulmonary fibrosis (IPF). Fast track designation is given to therapies that are intended to treat serious conditions and fill an unmet medical need.
Get regular updates to your inbox.
